NCT00512239 Prognostic Evaluation of Inflammatory Polyarthritis of Recent Onset
| NCT ID | NCT00512239 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gilles Boire |
| Condition | Rheumatoid Arthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 1998-07 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 1998-07 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Inflammatory joint diseases are major causes of invalidity and morbidity. Rheumatoid arthritis (RA), the most frequent of chronic arthritides, affects close to 1% of the Canadian population. Direct and indirect costs of RA represent close to 1% of the gross national product. Recent evidence suggest that initiation of early (e.g., during the first 3-12 months of disease) aggressive treatment decreases both mortality and long term invalidity in RA and other chronic arthritides. However, a significant proportion of patients with early polyarthritis (EPA) have a benign evolution, even if they fulfill criteria for RA. On the contrary, most patients whose arthritis persist for more than 12 months have a progressive and destructive disease. Currently available clinical, serological and genetic markers of severity in arthritic patients perform poorly in EPA patients to identify those patients whose arthritis is likely to persist and thus who deserve an aggressive treatment. The Investigators propose a prospective and longitudinal study to define the contribution of detection of rheumatoid arthritis-specific autoantibodies (RASA), either alone or in combination with other markers of severity, in the prognostic evaluation of patients presenting with EPA. Availability of such an effective serological tool to establish prognosis in individual patients would improve therapeutic decisions in clinical practice. The same prognostic tools would represent very powerful instruments to subset patients into more homogeneous groups in clinical trials, increasing their power.
Eligibility Criteria
Inclusion Criteria: * Early Rheumatoid arthritis * Early Inflammatory Arthritis Exclusion Criteria: * Refusal or inability to consent * Infectious arthritis * Microcrystalline arthritis
Contact & Investigator
Gilles Boire, MD, MSc
PRINCIPAL INVESTIGATOR
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Frequently Asked Questions
Who can join the NCT00512239 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Rheumatoid Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00512239 currently recruiting?
Yes, NCT00512239 is actively recruiting participants. Contact the research team at Gilles.Boire@USherbrooke.ca for enrollment information.
Where is the NCT00512239 trial being conducted?
This trial is being conducted at Sherbrooke, Canada.
Who is sponsoring the NCT00512239 clinical trial?
NCT00512239 is sponsored by Gilles Boire. The principal investigator is Gilles Boire, MD, MSc at Centre de recherche du Centre hospitalier universitaire de Sherbrooke. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.